Thumbnail Image
Item

Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis

Ryder, Jonathan H.
; 
Tong, Steven Y.C.
; 
Gallagher, Jason C.
; 
McDonald, Emily G.
; 
Thevarajan, Irani
; 
Lee, Todd C.
; 
Cortes-Penfield, Nicolas W.
Citations
Altmetric:
Genre
Journal article
Date
2022-10-31
Advisor
Committee member
Group
Department
Pharmacy Practice
Subject
Endocarditis
 Gentamicin
 Prosthetic valve
 Rifampin
 Staphylococcus
Permanent link to this record
http://hdl.handle.net/20.500.12613/8233
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
Gallagher-JournalArticle-2022.pdf
Adobe PDF, 369.48 KB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1093/ofid/ofac583
Abstract
Background: Based primarily on in vitro and animal models, with little data directly addressing patient outcomes, current guidelines recommend treating staphylococcal prosthetic valve endocarditis (PVE) with antibiotic combinations including gentamicin and rifampin. Here, we synthesize the clinical data on adjunctive rifampin and gentamicin in staphylococcal PVE. Methods: We conducted a systematic review and meta-analysis of PubMed- and Cochrane-indexed studies reporting outcomes of staphylococcal PVE treated with adjunctive rifampin, gentamicin, both agents, or neither (ie, glycopeptide or β-lactam monotherapy). We recorded outcomes including mortality, relapsed infection, length of stay, nephrotoxicity, hepatotoxicity, and important drug–drug interactions (DDIs). Results: Four relevant studies were identified. Two studies (n = 117) suggested that adding gentamicin to rifampin-containing regimens did not reduce clinical failure (odds ratio [OR], 0.98 [95% confidence interval {CI}, .39–2.46]), and 2 studies (n = 201) suggested that adding rifampin to gentamicin-containing regimens did not reduce clinical failure (OR, 1.29 [95% CI, .71–2.33]). Neither gentamicin nor rifampin was associated with reduced infection relapse; 1 study found that rifampin treatment was associated with longer hospitalizations (mean, 31.3 vs 42.3 days; P < .001). Comparative safety outcomes were rarely reported, but 1 study found rifampin to be associated with hepatoxicity, nephrotoxicity, and DDIs, leading to treatment discontinuation in 31% of patients. Conclusions: The existing clinical data do not suggest a benefit of either adjunctive gentamicin or rifampin in staphylococcal PVE. Given that other studies also suggest these agents add nephrotoxicity, hepatoxicity, and risk of DDIs without benefit in staphylococcal endovascular infections, we suggest that recommendations for gentamicin and rifampin in PVE be downgraded and primarily be used within the context of clinical trials.
Description
Citation
Jonathan H Ryder, Steven Y C Tong, Jason C Gallagher, Emily G McDonald, Irani Thevarajan, Todd C Lee, Nicolás W Cortés-Penfield, Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis, Open Forum Infectious Diseases, Volume 9, Issue 11, November 2022, ofac583, https://doi.org/10.1093/ofid/ofac583
Citation to related work
Oxford University Press
Has part
Open Forum Infectious Diseases, Vol. 9, Iss. 11
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos